{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:38:09Z","timestamp":1793147889954,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s41669-025-00565-3","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T20:40:32Z","timestamp":1742416832000},"page":"445-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Costs and Complications of Respiratory Syncytial Virus and Acute Respiratory Infections in the Adult Population: Analysis of a German Claims Database"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6321-7296","authenticated-orcid":false,"given":"Pavo","family":"Marijic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Kliemt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Last","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ambrosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Ewig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rembert","family":"Koczulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Schelling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Vogelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Waize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Stierl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jo\u00e3o","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pedron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alen","family":"Marijam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"565_CR1","unstructured":"RKI. RSV-Infektionen. 2024. Accessed: March 24, 2024. Available from: https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Merkblaetter\/Ratgeber_RSV.html"},{"issue":"12","key":"565_CR2","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1093\/infdis\/jit839","volume":"209","author":"AR Falsey","year":"2014","unstructured":"Falsey AR, McElhaney JE, Beran J, van Essen GA, Duval X, Esen M, et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis. 2014;209(12):1873\u201381. https:\/\/doi.org\/10.1093\/infdis\/jit839.","journal-title":"J Infect Dis"},{"issue":"4","key":"565_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40266-015-0258-9","volume":"32","author":"AR Branche","year":"2015","unstructured":"Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging. 2015;32(4):261\u20139. https:\/\/doi.org\/10.1007\/s40266-015-0258-9.","journal-title":"Drugs Aging"},{"issue":"Suppl 7","key":"565_CR4","doi-asserted-by":"publisher","first-page":"S577","DOI":"10.1093\/infdis\/jiz059","volume":"222","author":"T Shi","year":"2020","unstructured":"Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, et al. Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis. 2020;222(Suppl 7):S577\u201383. https:\/\/doi.org\/10.1093\/infdis\/jiz059.","journal-title":"J Infect Dis"},{"issue":"6","key":"565_CR5","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/cid\/ciab595","volume":"74","author":"AR Branche","year":"2022","unstructured":"Branche AR, Saiman L, Walsh EE, Falsey AR, Sieling WD, Greendyke W, et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017\u20132020. Clin Infect Dis. 2022;74(6):1004\u201311. https:\/\/doi.org\/10.1093\/cid\/ciab595.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"565_CR6","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1093\/infdis\/jiab040","volume":"226","author":"T Shi","year":"2022","unstructured":"Shi T, Vennard S, Jasiewicz F, Brogden R, Nair H, for the Resceu Investigators. Disease burden estimates of respiratory syncytial virus related acute respiratory infections in adults with comorbidity: a systematic review and meta-analysis. J Infect Dis. 2022;226(Suppl 1):S17\u201321. https:\/\/doi.org\/10.1093\/infdis\/jiab040.","journal-title":"J Infect Dis"},{"issue":"1","key":"565_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13031","volume":"17","author":"M Savic","year":"2023","unstructured":"Savic M, Penders Y, Shi T, Branche A, Pircon JY. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis. Influenza Other Respir Viruses. 2023;17(1): e13031. https:\/\/doi.org\/10.1111\/irv.13031.","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"565_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12913-018-3066-1","volume":"18","author":"C Amand","year":"2018","unstructured":"Amand C, Tong S, Kieffer A, Kyaw MH. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis. BMC Health Serv Res. 2018;18(1):294. https:\/\/doi.org\/10.1186\/s12913-018-3066-1.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"565_CR9","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/infdis\/jiaa183","volume":"222","author":"B Ackerson","year":"2020","unstructured":"Ackerson B, An J, Sy LS, Solano Z, Slezak J, Tseng HF. Cost of hospitalization associated with respiratory syncytial virus infection versus influenza infection in hospitalized older adults. J Infect Dis. 2020;222(6):962\u20136. https:\/\/doi.org\/10.1093\/infdis\/jiaa183.","journal-title":"J Infect Dis"},{"issue":"6","key":"565_CR10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s40273-022-01142-w","volume":"40","author":"E Rafferty","year":"2022","unstructured":"Rafferty E, Paulden M, Buchan SA, Robinson JL, Bettinger JA, Kumar M, et al. Evaluating the individual healthcare costs and burden of disease associated with RSV across age groups. Pharmacoeconomics. 2022;40(6):633\u201345. https:\/\/doi.org\/10.1007\/s40273-022-01142-w.","journal-title":"Pharmacoeconomics"},{"key":"565_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2023.105399","volume":"161","author":"A Ambrosch","year":"2023","unstructured":"Ambrosch A, Luber D, Klawonn F, Kabesch M. Focusing on severe infections with the respiratory syncytial virus (RSV) in adults: Risk factors, symptomatology and clinical course compared to influenza A\/B and the original SARS-CoV-2 strain. J Clin Virol. 2023;161: 105399. https:\/\/doi.org\/10.1016\/j.jcv.2023.105399.","journal-title":"J Clin Virol"},{"issue":"4","key":"565_CR12","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/v15040877","volume":"15","author":"M H\u00f6nemann","year":"2023","unstructured":"H\u00f6nemann M, Thiem S, Bergs S, Berthold T, Propach C, Siekmeyer M, et al. In-depth analysis of the re-emergence of respiratory syncytial virus at a tertiary care hospital in Germany in the summer of 2021 after the alleviation of non-pharmaceutical interventions due to the SARS-CoV-2 pandemic. Viruses. 2023;15(4):877. https:\/\/doi.org\/10.3390\/v15040877.","journal-title":"Viruses"},{"key":"565_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad546","author":"TF Schwarz","year":"2023","unstructured":"Schwarz TF, Hwang SJ, Ylisastigui P, Liu CS, Takazawa K, Yono M, et al. Immunogenicity and safety following one dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: a phase 3 trial. J Infect Dis. 2023. https:\/\/doi.org\/10.1093\/infdis\/jiad546.","journal-title":"J Infect Dis"},{"issue":"16","key":"565_CR14","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","volume":"388","author":"EE Walsh","year":"2023","unstructured":"Walsh EE, Perez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465\u201377. https:\/\/doi.org\/10.1056\/NEJMoa2213836.","journal-title":"N Engl J Med"},{"key":"565_CR15","unstructured":"European Medicines Agency. Arexvy. Amsterdam, NL: EMA; 2023 June 6, 2023. Document: EMEA\/H\/C\/006054. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/arexvy#ema-inpage-item-authorisation-details."},{"key":"565_CR16","unstructured":"European Medicines Agency. Abrysvo. Amsteradm, NL: EMA; 2023 August 23, 2023. Document: EMEA\/H\/C\/006027 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abrysvo#ema-inpage-item-authorisation-details."},{"issue":"1","key":"565_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s15010-023-02141-5","volume":"52","author":"M Addo","year":"2024","unstructured":"Addo M, Cornely O, Denkinger M, Ertl G, Herold S, Pletz M, et al. RSV vaccination strategies for high-risk patients 2023: a collaborative position paper by leading German medical societies and organizations. Infection. 2024;52(1):285\u20138. https:\/\/doi.org\/10.1007\/s15010-023-02141-5.","journal-title":"Infection"},{"key":"565_CR18","unstructured":"Davies K. Population of Germany as of December 31, 2022, by age group. 2024. Accessed: July 30, 2024 Available from: https:\/\/www.statista.com\/statistics\/454349\/population-by-age-group-germany\/"},{"key":"565_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.25646\/12470","volume":"32","author":"A Falman","year":"2024","unstructured":"Falman A, Sch\u00f6nfeld V, Flasche S, G\u00fcnther F, Koch J, Kwetkat A, et al. Beschluss zur empfehlung der STIKO f\u00fcr eine standardimpfung gegen erkrankungen durch Respiratorische Synzytial-Viren (RSV) f\u00fcr personen \u2265 75 jahre sowie zur indikationsimpfung von personen im alter von 60 bis 74 jahren mit risikofaktoren. Epid Bull. 2024;32:3\u201328. https:\/\/doi.org\/10.25646\/12470.","journal-title":"Epid Bull"},{"key":"565_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-01006-0","author":"S Scholz","year":"2024","unstructured":"Scholz S, Dobrindt K, Tufts J, Adams S, Ghaswalla P, Ultsch B, et al. The burden of Respiratory Syncytial Virus (RSV) in Germany: a comprehensive data analysis suggests underdetection of hospitalisations and deaths in adults 60 years and older. Infect Dis Ther. 2024. https:\/\/doi.org\/10.1007\/s40121-024-01006-0.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"565_CR21","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/irv.12665","volume":"14","author":"W Cai","year":"2020","unstructured":"Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, et al. Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance. Influenza Other Respir Viruses. 2020;14(6):630\u20137. https:\/\/doi.org\/10.1111\/irv.12665.","journal-title":"Influenza Other Respir Viruses"},{"issue":"6","key":"565_CR22","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/irv.12729","volume":"14","author":"W Cai","year":"2020","unstructured":"Cai W, Buda S, Schuler E, Hirve S, Zhang W, Haas W. Risk factors for hospitalized respiratory syncytial virus disease and its severe outcomes. Influenza Other Respir Viruses. 2020;14(6):658\u201370. https:\/\/doi.org\/10.1111\/irv.12729.","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"565_CR23","doi-asserted-by":"publisher","first-page":"1958610","DOI":"10.1080\/21645515.2021.1958610","volume":"18","author":"GK Balasubramani","year":"2022","unstructured":"Balasubramani GK, Nowalk MP, Eng H, Zimmerman RK. Estimating the burden of adult hospitalized RSV infection using local and state data - methodology. Hum Vaccin Immunother. 2022;18(1):1958610. https:\/\/doi.org\/10.1080\/21645515.2021.1958610.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"565_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1055\/s-0034-1396815","volume":"77","author":"E Swart","year":"2015","unstructured":"Swart E, Gothe H, Geyer S, Jaunzeme J, Maier B, Grobe TG, et al. Good Practice of Secondary Data Analysis (GPS): guidelines and recommendations. Gesundheitswesen. 2015;77(2):120\u20136. https:\/\/doi.org\/10.1055\/s-0034-1396815.","journal-title":"Gesundheitswesen"},{"key":"565_CR25","unstructured":"WIG2 Institut. WIG2 - Analysen im Gesundheitssystem. 2024. Accessed: January 29, 2024. Available from: https:\/\/www.wig2.de\/"},{"issue":"11","key":"565_CR26","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1007\/s00103-016-2454-0","volume":"59","author":"K Kopke","year":"2016","unstructured":"Kopke K, Prahm K, Buda S, Haas W. Evaluation of an ICD-10-based electronic surveillance of acute respiratory infections (SEED(ARI)) in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016;59(11):1484\u201391. https:\/\/doi.org\/10.1007\/s00103-016-2454-0.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"1","key":"565_CR27","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1186\/s12889-019-7458-x","volume":"19","author":"S Scholz","year":"2019","unstructured":"Scholz S, Damm O, Schneider U, Ultsch B, Wichmann O, Greiner W. Epidemiology and cost of seasonal influenza in Germany\u2014a claims data analysis. BMC Public Health. 2019;19(1):1090. https:\/\/doi.org\/10.1186\/s12889-019-7458-x.","journal-title":"BMC Public Health"},{"key":"565_CR28","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.2147\/COPD.S322036","volume":"16","author":"CF Vogelmeier","year":"2021","unstructured":"Vogelmeier CF, Diesing J, Kossack N, Pignot M, Friedrich FW. COPD exacerbation history and impact on future exacerbations\u20148-year retrospective observational database cohort study from Germany. Int J Chron Obstruct Pulmon Dis. 2021;16:2407\u201317. https:\/\/doi.org\/10.2147\/COPD.S322036.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"7","key":"565_CR29","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"A Papi","year":"2023","unstructured":"Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388(7):595\u2013608. https:\/\/doi.org\/10.1056\/NEJMoa2209604.","journal-title":"N Engl J Med"},{"issue":"1","key":"565_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13054","volume":"17","author":"O Damm","year":"2023","unstructured":"Damm O, Krefft A, Ahlers J, Kramer R, Witte J, Batram M, et al. Prevalence of chronic conditions and influenza vaccination coverage rates in Germany: results of a health insurance claims data analysis. Influenza Other Respir Viruses. 2023;17(1): e13054. https:\/\/doi.org\/10.1111\/irv.13054.","journal-title":"Influenza Other Respir Viruses"},{"key":"565_CR31","unstructured":"German Federal Statistical Office. Preise: Verbraucherpreisindex und Inflationsrate 2024. Accessed: April 26, 2024. Available from: https:\/\/www.destatis.de\/DE\/Themen\/Wirtschaft\/Preise\/Verbraucherpreisindex\/_inhalt.html#238920"},{"key":"565_CR32","unstructured":"Exchange-rates.org. Euro (EUR) To US Dollar (USD) Exchange Rate History for 2014. 2024. Accessed: February 12, 2024. Available from: https:\/\/www.exchange-rates.org\/exchange-rate-history\/eur-usd-2014"},{"key":"565_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-023-02122-8","author":"P Niekler","year":"2023","unstructured":"Niekler P, Goettler D, Liese JG, Streng A. Hospitalizations due to respiratory syncytial virus (RSV) infections in Germany: a nationwide clinical and direct cost data analysis (2010\u20132019). Infection. 2023. https:\/\/doi.org\/10.1007\/s15010-023-02122-8.","journal-title":"Infection"},{"key":"565_CR34","unstructured":"Exchange Rates UK. US Dollar to Euro Spot Exchange Rates for 2013. 2024. Accessed: February 12, 2024. Available from: https:\/\/www.exchangerates.org.uk\/USD-EUR-spot-exchange-rates-history-2013.html"},{"key":"565_CR35","unstructured":"OECD. Health at a Glance 2023 - OECD indicators. Paris, FR: The Organization for Economic Cooperation and Development; 2023. Document."},{"issue":"4","key":"565_CR36","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40121-024-00951-0","volume":"13","author":"A Polkowska-Kramek","year":"2024","unstructured":"Polkowska-Kramek A, Begier E, Bruyndonckx R, Liang C, Beese C, Brestrich G, et al. Estimated incidence of hospitalizations and deaths attributable to respiratory syncytial virus infections among adults in Germany between 2015 and 2019. Infect Dis Ther. 2024;13(4):845\u201360. https:\/\/doi.org\/10.1007\/s40121-024-00951-0.","journal-title":"Infect Dis Ther"},{"issue":"Suppl 1","key":"565_CR37","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1093\/infdis\/jiac069","volume":"226","author":"Z Mao","year":"2022","unstructured":"Mao Z, Li X, Korsten K, Bont L, Butler C, Wildenbeest J, et al. Economic burden and health-related quality of life of respiratory syncytial virus and influenza infection in European community-dwelling older adults. J Infect Dis. 2022;226(Suppl 1):S87-94. https:\/\/doi.org\/10.1093\/infdis\/jiac069.","journal-title":"J Infect Dis"},{"issue":"1","key":"565_CR38","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1186\/s40001-023-01482-z","volume":"28","author":"C Quarg","year":"2023","unstructured":"Quarg C, Jorres RA, Engelhardt S, Alter P, Budweiser S. Characteristics and outcomes of patients hospitalized for infection with influenza, SARS-CoV-2 or respiratory syncytial virus in the season 2022\/2023 in a large German primary care centre. Eur J Med Res. 2023;28(1):568. https:\/\/doi.org\/10.1186\/s40001-023-01482-z.","journal-title":"Eur J Med Res"},{"issue":"3","key":"565_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264890","volume":"17","author":"SA Kujawski","year":"2022","unstructured":"Kujawski SA, Whitaker M, Ritchey MD, Reingold AL, Chai SJ, Anderson EJ, et al. Rates of respiratory syncytial virus (RSV)-associated hospitalization among adults with congestive heart failure-United States, 2015\u20132017. PLoS\u00a0One. 2022;17(3): e0264890. https:\/\/doi.org\/10.1371\/journal.pone.0264890.","journal-title":"PLoS\u00a0One"},{"issue":"3","key":"565_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3109\/15412555.2012.744741","volume":"10","author":"J Mehta","year":"2013","unstructured":"Mehta J, Walsh EE, Mahadevia PJ, Falsey AR. Risk factors for respiratory syncytial virus illness among patients with chronic obstructive pulmonary disease. COPD. 2013;10(3):293\u20139. https:\/\/doi.org\/10.3109\/15412555.2012.744741.","journal-title":"COPD"},{"issue":"4","key":"565_CR41","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.283.4.499","volume":"283","author":"WP Glezen","year":"2000","unstructured":"Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000;283(4):499\u2013505. https:\/\/doi.org\/10.1001\/jama.283.4.499.","journal-title":"JAMA"},{"issue":"10","key":"565_CR42","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/thx.2005.045187","volume":"61","author":"PA Wark","year":"2006","unstructured":"Wark PA, Gibson PG. Asthma exacerbations - 3: Pathogenesis. Thorax. 2006;61(10):909\u201315. https:\/\/doi.org\/10.1136\/thx.2005.045187.","journal-title":"Thorax"},{"issue":"2","key":"565_CR43","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/cid\/ciy991","volume":"69","author":"B Ackerson","year":"2019","unstructured":"Ackerson B, Tseng HF, Sy LS, Solano Z, Slezak J, Luo Y, et al. Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. Clin Infect Dis. 2019;69(2):197\u2013203. https:\/\/doi.org\/10.1093\/cid\/ciy991.","journal-title":"Clin Infect Dis"},{"key":"565_CR44","unstructured":"The Commonwealth Fund. International Health Care System Profiles -Germany. 2020. Accessed: June 27, 2024. Available from: https:\/\/www.commonwealthfund.org\/international-health-policy-center\/countries\/germany"},{"issue":"5","key":"565_CR45","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/irv.12996","volume":"16","author":"W Cai","year":"2022","unstructured":"Cai W, Durrwald R, Biere B, Schweiger B, Haas W, Wolff T, et al. Determination of respiratory syncytial virus epidemic seasons by using 95% confidence interval of positivity rates, 2011\u20132021, Germany. Influenza Other Respir Viruses. 2022;16(5):854\u20137. https:\/\/doi.org\/10.1111\/irv.12996.","journal-title":"Influenza Other Respir Viruses"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00565-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00565-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00565-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:58:40Z","timestamp":1745855920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00565-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00565-3","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"30 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GSK funded this study (VEO-000566) and was involved in all stages of study conduct, including analysis of the data. GSK also took charge of all costs associated with the development and publication of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"For requests for access to anonymized subject-level data, please contact the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"MK, MW, SP, and PM are employed by GSK. AM, MJF, and MS are employed by GSK and hold financial equities in GSK. TL was employed by GSK at the time of the study and held financial equities in GSK, and is now employed by the National Health Care Institute, Diemen, Netherlands. AA received payment or honoraria for lectures from GSK. JS received consulting fees from GSK, MSD, Sanofi, Pfizer, Novavax, Bavarian Nordic, and Seqirus; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GSK, MSD, Sanofi, Pfizer, BioNTech, Moderna, Novavax, Takeda, Bavarian Nordic, Viatris, Seqirus, Novartis, and Janssen; support for attending meetings and\/or travel from Sanofi and Pfizer; participated on a Data Safety Monitoring Board or Advisory Board at GSK, MSD, Sanofi, Pfizer, Moderna, Novavax, Bavarian Nordic, and Viatris. SE received payment or honoraria for lectures and presentations from GSK; the author declares to be author and coauthor of respiratory guidelines (unpaid). CV received grants or contracts for his institution from the German Ministry of Education and Science (BMBF), AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GSK, Grifols, and Novartis; consulting fees from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GSK, Insmed, Menarini, Novartis, Nuvaira, Roche, and Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GSK, Insmed, Menarini, Novartis, Roche, and Sanofi. NK is an employee of ZEG Berlin, which received funding from GSK for the conduct of the study. RK is an employee of WIG2, which received funding from GSK for the conduct of the study. RKo received grants or contracts for his institution from the German Ministry of Education and Science (BMBF), Bavarian government, Boehringer Ingelheim, Chiesi, CSL Behring, GSK, Grifols, and Bosch; consulting fees from AstraZeneca, Biontech, Boehringer Ingelheim, CSL Behring, Chiesi, GSK, Menarini, Nuvaira, Pfizer, and Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GSK, Menarini, Pfizer, PulmonX, and Sanofi. The authors declare no other financial and non-financial relationships and activities.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"All authors participated in the design or implementation or analysis; interpretation of the study; and the development of this manuscript. All authors had full access to the data and gave final approval before submission. All authors agree to be accountable for all aspects of the work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contributorship"}},{"value":"AREXVY is a trademark owned by or licensed to GSK. ABRYSVO is a trademark of Pfizer. mRESVIA is a trademark of Moderna.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trademarks"}},{"value":"Poster presentation at Ethics and Economics in the Health Care System, the 16th annual conference of the German Health Economics Association (DGG\u00d6), 4-5 March 2024, Halle (Saale), Germany.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous congress activities"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":11,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}